共 50 条
- [21] Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 503 (04) : 2912 - 2917Ma, RuiYun, Cai-Hong
- [22] Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid TumorsCLINICAL CANCER RESEARCH, 2021, 27 (10) : 2723 - 2733Wick, AntjeBaehr, OliverSchuler, MartinRohrberg, KristofferChawla, Sant P.Janku, FilipSchiff, DavidHeinemann, VolkerNarita, YoshitakaLenz, Heinz-JosefIkeda, MasafumiAndo, YuichiWick, WolfgangSteinbach, Joachim P.Burger, Michael C.Wenger, KatharinaLassen, UlrikSankhala, Kamalesh K.Roggia, CristianaGenvresse, IsabelleMunhoz, CatyaRentzsch, ChristineReschke, SusanneLanger, SimonWagner, MarkusKaulfuss, StefanCai, CharlesLagkadinou, EleniJeffers, MichaelPena, CarolTabatabai, Ghazaleh
- [23] A novel inhibitor of IDH1 abrogates 2-HG production and reverses aberrant epigenetic alterations in IDH1 mutant cellsCANCER RESEARCH, 2015, 75Rominger, CynthiaQuinn, ChadGao, EnochPietrak, BethRendina, AlanSmallwood, AngelaGroy, ArthurKorenchuk, SusanMcHugh, CharlesWiggall, KenReif, AlexanderSchmidt, StanleyQi, HongweiZhao, HuizhenConcha, NestorCarpenter, ChristopherLuengo, JuanKruger, RyanSchwartz, BenjaminAdams, NicholasMcCabe, Michael T.
- [24] Phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001b in patients with recurrent or progressive IDH1 mutant gliomas.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Natsume, AtsushiWakabayashi, ToshihikoMiyakita, YasujiNarita, YoshitakaMineharu, YoheiArakawa, YoshikiYamasaki, FumiyukiSugiyama, KazuhikoHata, NobuhiroMuragaki, YoshihiroNishikawa, RyoShinojima, NaokiKumabe, ToshihiroSaito, RyutaIto, KazumiTachibana, MasayaKakurai, YasuyukiNishijima, SoichiroTsubouchi, Hiroshi
- [25] Mutant isocitrate dehydrogenase 1 (IDH1) inhibitor synergistically prolongs animal survival with standard therapies in patient-derived IDH1 mutant glioma xenograft mouse modelsCANCER RESEARCH, 2017, 77Kogiso, MariQi, LinZhang, HuiyuanBraun, Frank K.Du, YuchenHuang, YulunLindsay, HollyZhao, SiboInjac, Sarah G. G.Liu, ZhenBaxter, Patricia A.Su, Jack M.Perlaky, LaszloParsons, D. WilliamsChintagumpala, MuraliAdesina, AdekunleWang, JialiangSong, YongchengLi, Xiao-Nan
- [26] Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including gliomaJOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Mellinghoff, Ingo K.Penas-Prado, MartaPeters, Katherine B.Cloughesy, Timothy FrancisBurris, Howard A.Maher, Elizabeth A.Janku, FilipCote, Gregory MichaelDe La Fuente, Macarena InesClarke, JenniferSteelman, LoriLe, KhaZhang, YanweiSonderfan, AlisonHummel, DianaSchoenfeld, StevenYen, KatharinePandya, Shuchi SumantWen, Patrick Y.
- [28] Quantitation of Ivosidenib, A Novel Mutant IDH1 Inhibitoron Mice DBS: Application to a Pharmacokinetic StudyDRUG RESEARCH, 2019, 69 (09) : 505 - 511Dittakavi, SreekanthJat, Rakesh KumarMullangi, Ramesh
- [29] Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumorsINVESTIGATIONAL NEW DRUGS, 2020, 38 (02) : 433 - 444Fan, BinMellinghoff, Ingo K.Wen, Patrick Y.Lowery, Maeve A.Goyal, LipikaTap, William D.Pandya, Shuchi S.Manyak, ErikaJiang, LiewenLiu, GuowenNimkar, TaraGliser, CameliaJudge, Molly PrahlAgresta, SamYang, HuaDai, David
- [30] Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumorsInvestigational New Drugs, 2020, 38 : 433 - 444Bin FanIngo K. MellinghoffPatrick Y. WenMaeve A. LoweryLipika GoyalWilliam D. TapShuchi S. PandyaErika ManyakLiewen JiangGuowen LiuTara NimkarCamelia GliserMolly Prahl JudgeSam AgrestaHua YangDavid Dai